Executive summary: Evaluating drug company copay assistance programs

• Manufacturer copay assistance programs represent a meaningful component of commercial investment for many life sciences companies and can play an important role in patient affordability and brand access. Because these programs also often involve operational complexity and rapidly changing market dynamics, manufacturers need a structured basis for evaluating whether program design remains well matched to current conditions.
• This paper focuses on a practical question: How can manufacturers structure the design and review of copay programs in a way that supports informed decision making? We provide a structured approach to evaluating program parameters, oversight practices, and analytic inputs relative to current market conditions. The framework focuses on four areas: competitive landscape, out-of-pocket sensitivity, coverage landscape, and alternative funding mechanisms.
• This paper does not take a position on the broader policy merits of copay assistance programs, nor does it advocate for or against the range of responses that have developed across the market. Those questions involve nuanced trade-offs across stakeholders and are outside the scope of this discussion. This discussion is intended for manufacturer audiences responsible for these decisions and is offered as a framework for evaluation, not as a recommendation for or against any specific program design or vendor model.

How drug manufacturer copay assistance programs work

Manufacturer copay assistance programs reduce a commercially insured patient’s prescription medication out-of-pocket cost at the point of dispense, with the remaining cost funded by the manufacturer. Programs vary in maximum annual benefit, monthly limits, patient pay structure, and eligibility rules. For specialty products, the combined cost of redeemed benefit and program operating expense can be material at the brand level.

Program governance typically involves a brand or market access team setting design parameters, a vendor or set of vendors operating the program, and a reporting cadence that informs ongoing adjustments. The boundaries among design, operations, and measurement have become less distinct as vendors have expanded their service offerings; as a result, manufacturers may benefit from structured review processes that explicitly separate these functions for analytic purposes.

Considerations about the drug copay services market

The copay services market includes hub providers, copay administrators, patient-engagement platforms, and specialty data aggregators; these services may be bundled by individual vendors or by affiliated entities. Consolidation has produced operational benefits—including streamlined patient journeys, integrated data flows, and simpler vendor management—that manufacturers reasonably value.

The same structure also introduces considerations that benefit from ongoing review:

• Fee structures linked to volume. Many copay administration agreements include per-claim transaction fees, and hub or patient-services agreements may include per-enrollment fees. Vendor revenue therefore tends to scale with program utilization, which is a relevant factor when the same vendor is also providing input on program design parameters that influence utilization.
• Reporting produced by the operator. Program performance reporting is commonly produced by the entity operating the program. Reporting tends to emphasize metrics that are readily available within the operator’s data, such as redemption volume, average benefit per claim, and enrollment counts, rather than metrics that require linkage to external data sources, such as incremental therapy starts attributable to the program or persistence relative to a matched nonenrolled cohort.
• Reference set limited to the vendor’s book. An individual vendor’s view of the market is shaped by the programs it operates. Benchmarks and design recommendations drawn from that book of business may not capture the full distribution of program designs in the market or the full range of patient and payer responses to them.

These considerations do not imply that integrated vendors provide lower-quality service or act other than in good faith. They describe the structural context in which design and measurement decisions are made, and they suggest that strategic review with input from a party outside the operating relationship may add value.

4 areas to consider when evaluating a drug copay assistance program

The following four areas commonly warrant thoughtful review. Each can be evaluated using available program data, supplemented where appropriate by external benchmarks and payer benefit-design intelligence.

1. Competitive landscape

Regular comparison of program parameters against the relevant competitive set helps confirm that benefit design remains appropriate given the affordability gap patients face relative to alternatives. The relevant comparison includes practical mechanics, such as patient pay observed at the point of dispense, enrollment friction, and time to first fill, in addition to published program terms.

Questions to evaluate:

• How do current program parameters compare with those of relevant competitor brands?
• What is the patient’s practical experience at the point of dispense, including time to first fill, friction in enrollment, and handling of bridging or re-enrollment?

2. Out-of-pocket sensitivity

Patient response to out-of-pocket cost varies by therapeutic area, channel, deductible status, and socioeconomic factors. Empirical evaluation of these inflection points helps identify the cost thresholds at which assistance is most likely to improve fulfillment, the thresholds beyond which marginal additional support is less likely to change outcomes, and segments where modest adjustments to patient pay may be feasible without meaningful behavioral impact. Published research has found that manufacturer offsets fully eliminated patient out-of-pocket cost in approximately one-third of observed claims,¹ highlighting the importance of understanding where support is most likely to influence behavior and where it may already exceed the amount needed to reduce access friction. This analysis often surfaces the most actionable opportunities for refinement of program parameters.

Questions to evaluate:

• At what cost thresholds does patient out-of-pocket exposure materially affect fill and persistence behavior?
• Where is additional manufacturer support most likely to improve fulfillment, and where is it likely to reach patients who would have filled without assistance?

3. Coverage landscape

The patient’s commercial benefit design determines the timing and magnitude of out-of-pocket exposure across the plan year. A coverage landscape view therefore links payer benefit design, formulary status, utilization management, and expected patient cost by month. Together, these inform when and how much support the program needs to provide. For example, products with less-favorable coverage, higher cost sharing, or more restrictive access requirements may require a different copay design response than one that is more accessible. Programs designed without explicit reference to this broader coverage view may provide more support than is needed in some settings and less than is needed in others.

Questions to evaluate:

• How does the patient’s commercial benefit design translate into expected out-of-pocket cost across the plan year, given formulary tier, deductible status, coinsurance versus copay, and specialty carve-out arrangements?
• How is the product covered across major plans relative to key competitors, and what does that imply for the level of manufacturer support likely to be needed?

4. Alternative funding mechanisms

Three mechanisms are particularly relevant:

• Copay accumulators do not credit manufacturer assistance toward the patient’s deductible, shifting cost back to the patient once the program maximum is reached.
• Copay maximizers spread the full annual program value evenly across the plan year, capturing the maximum manufacturer contribution regardless of the patient’s underlying cost sharing.
• Alternative funding programs (AFPs) carve specialty drugs out of the medical or pharmacy benefit and route patients toward charitable or manufacturer-funded programs designed for the uninsured or underinsured.

These mechanisms are not niche features of the commercial coverage landscape. As of 2022, 39% of commercially insured beneficiaries were enrolled in plans with copay accumulators, 41% in plans with copay maximizers, and 12% in plans with AFPs.² Each mechanism has different detection requirements and different design and operational responses. Intentional design review can establish a current estimate of exposure by mechanism and identify which patient cohorts and payer footprints are most affected, supporting decisions about program design parameters, claim-level routing logic, and patient communication.

Questions to evaluate:

• What share of program value is being captured by copay accumulators, maximizers, or AFPs?
• Which patient cohorts and payer footprints are most exposed, and what design or operational responses are available?

Drug manufacturer copay assistance programs: Approaches to initial design and periodic review

Manufacturers can structure both the initial design of copay programs and the periodic review of in-market programs in several ways. The appropriate approach depends on the size of the program, the complexity of the payer mix, the stage of the product, and the manufacturer’s internal analytic capabilities.

• Internal review. Brand or market access teams may conduct the review using internally available data and benchmarks. This approach is most feasible where the manufacturer has dedicated analytic resources and access to data beyond what the operating vendor provides.
• Vendor-led review. The operating vendor may produce a structured review using its own data and benchmarks. This approach is efficient and can be appropriate, particularly for programs that are not large enough to warrant additional analytic investment, but it does not separate the design and measurement function from the operational function.
• Independent review. An external party with no economic interest in program utilization conducts the review, drawing on program data, external benchmarks, and payer benefit-design intelligence. This approach separates design and measurement from operations and may be appropriate for larger programs, programs operating in complex payer environments, or programs where the manufacturer wants a defensible analytic basis for design decisions independent of the operating relationship.

These approaches are not mutually exclusive. A common pattern is operational reporting on a continuous basis from the operating vendor, supplemented by periodic independent review as needed based on program scale and changes in the relevant coverage and competitive environments.

5 considerations before implementing a drug copay assistance program

The following sequence describes a typical engagement structure for an independent or hybrid review. It can be adapted to in-flight programs or to pre-launch design.

1. Define the scope. Distinguish among assessment of current program design, assessment of vendor performance, and design recommendations for the next plan year. Each requires somewhat different data inputs and stakeholder participation.
2. Identify the reviewing party. Where independence is a design objective, the reviewing party should not have economic exposure to program utilization. This is typically achieved by engaging a consultancy, actuarial firm, or other advisor without an operating role in the program.
3. Assemble the data inputs. Inputs typically include claims-level program data, enrollment and abandonment data, payer benefit-design intelligence, channel mix, and competitive program terms. Where some inputs are sourced from the operating vendor, the engagement plan should anticipate access logistics and identify opportunities for independent triangulation.
4. Translate findings into design and contract terms. Outputs are typically expressed in terms of maximum annual benefit, patient pay structure, eligibility criteria, accumulator and maximizer detection rules, AFP response logic, and the metric set used to govern the program going forward.
5. Establish an approach for periodic reassessment. Coverage landscapes shift, accumulator and maximizer adoption continue to evolve, and AFP penetration varies by region and employer segment. Manufacturers should determine the timing of that reassessment based on their own planning cycle, market dynamics, and decision needs.

Conclusions: Final thoughts on copay assistance program design for drug manufacturers

• Copay assistance programs are a meaningful component of commercial investment for many pharmaceutical manufacturers and can materially influence patient affordability, brand access, and the efficiency with which support dollars are deployed. In a market shaped by changing reimbursement dynamics, evolving payer responses, and increasingly connected vendor models, strategic review of copay program design has become an important part of sound program governance.
• A structured review can help manufacturers assess whether current program parameters remain aligned with competitive realities, patient out-of-pocket sensitivity, product coverage across major plans relative to competitors, and exposure to accumulators, maximizers, and alternative funding programs.
• Manufacturers should approach copay program design and refinement with a level of analytic support that matches the financial and strategic importance of these programs. The objective is to ensure that design decisions, whether made at launch or revisited over time, are grounded in a broad view of market conditions, payer complexity, competitive positioning, and patient affordability dynamics. For many manufacturers, that means engaging structured outside support to inform program strategy, oversight, and next-step design decisions.

References

  ¹ Sen, A. P., Kang, S.-Y., Rashidi, E., Ganguli, D., Anderson, G., & Alexander, G. C. (2021). Characteristics of copayment offsets for prescription drugs in the United States. JAMA Internal Medicine, 181(6), 758–764. Retrieved June 2, 2026, from https://doi:10.1001/jamainternmed.2021.0733.  

  ² Choi, D., et al. (2024). A primer on copay accumulators, copay maximizers, and alternative funding programs. Journal of Managed Care & Specialty Pharmacy, 30(8), 883–896. Retrieved June 2, 2026, from https://doi:10.18553/jmcp.2024.30.8.883.

About this paper

This paper is intended for pharmaceutical manufacturer market access, finance, and brand leadership audiences considering copay program design and oversight. It does not constitute legal, actuarial, or compliance advice. Specific recommendations for initial program design or subsequent refinement require analysis grounded in brand-, channel-, and payer-specific data.